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URINARY TYPE II COLLAGEN C-TERMINAL PEPTIDE IS ELEVATED
AFTER ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION AND
ASSOCIATED WITH KNEE SYMPTOMS AND FUNCTION
T.L. Chmielewski1, T.N. Trumble2, A.M. Joseph1, J.J. Shuster1,
P.A. Indelicato1, M.W. Moser1, F.M. Cicuttini3, C. Leeuwenburgh1. 1Univ.
of Florida, Gainesville, FL, USA; 2Univ. of Minnesota, St. Paul, MN, USA;
3Monash Univ., Melbourne, Australia
Purpose: Elevated levels of C-terminal crosslinking telopeptide of type
II collagen in urine (uCTX-II) are associated with the development and
progression of knee osteoarthritis (OA). Knee OA is prevalent following
anterior cruciate ligament reconstruction (ACLR), but uCTX-II levels have
not been studied in this population. The purpose of this study was to
1) compare uCTX-II levels between patients with ACLR and uninjured
controls, and 2) determine if uCTX-II levels are associated with self-
report of knee symptoms and function in patients with ACLR.
Methods: Subjects included 28 patients with ACLR (14 males/14 females;
mean age = 19.6±4.5 years) that participated in at least 50 hours/year
of high-demand sports before injury (i.e. those that involve cutting,
jumping and pivoting) and 28 uninjured controls matched by age
(± 2 years), gender and participation in high-demand sports. Testing
was conducted at 4 time points spaced 4 weeks apart and the
following were collected: demographic information (height, weight,
surgical variables); early morning, fasting, second-void urine; and
responses on the International Knee Documentation Committee (IKDC)
subjective knee form, which includes questions about knee symptoms
and function. The time points equated to 4, 8, 12 and 16 weeks
post-surgery for subjects with ACLR. uCTX-II levels were determined
with commercially available enzyme-linked immunosorbent assay (Urine
CartiLaps; Nordic Bioscience, Denmark) and corrected for creatinine
level. Log transformation was performed prior to analysis. To compare
uCTX-II levels between groups, the average value across time points
was computed and used as the dependent variable in a General Linear
Model. To compare the change in uCTX-II levels over time between
groups, UCTX-II was plotted against time and the slope used as the
dependent variable in a General Linear Model. Body mass index was a
covariate in both models. IKDC knee form scores were plotted against
time, and the Pearson’s correlation coefﬁcient for the slope and the slope
of uCTX-II:time was determined.
Results: For subjects with ACLR, there were 17 autografts and 11
allografts, and the mean time from injury to surgery was 70±64 days.
The average uCTX-II levels were higher in subjects with ACLR
compared to controls (3223.8±3543.9 and 2827.8±5033.7 ng/mmol,
respectively; p = 0.039), but the uCTX-II: time slope was not signiﬁcantly
different between groups (−0.033±0.059 and −0.019±0.093, respectively;
p = 0.521). IKDC scores improved over time in subjects with ACLR (45.5,
57.6, 66.5, and 73.7). A signiﬁcant negative correlation was found
between the IKDC:time and uCTX-II:time slopes (−0.402, p = 0.034).
Conclusions: uCTX-II levels in the early period following ACLR are
elevated when compared to participants in high-demand sports.
Although uCTX-II levels tended to decrease from 4 to 16 weeks post-
surgery, the rate of decline was not greater than the variability in
controls. A decrease in uCTX-II over time was associated with less
severe knee symptoms and better knee function. These data warrant
further study of uCTX-II in the development of knee OA following ACL
reconstruction.
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REPEATED MEASUREMENTS OF uCTX-II, sCOMP, uCTX-I, AND hsCRP
AS BIOMARKERS OF PROGRESSION IN OSTEOARTHRITIS
E. Yusuf1, I. Meulenbelt1, B. van El2, M-P. Hellio le Graverand3,
J. Bijsterbosch1, E.J. van Langelaan4, F.R. Rosendaal1, E.P. Slagboom1,
T.W. Huizinga1, M. Kloppenburg1. 1Leiden Univ. Med. Ctr., Leiden,
Netherlands; 2TNO Quality of Life, Leiden, Netherlands; 3Pﬁzer Inc, Groton,
CT, USA; 4Rijnland Hosp., Leiderdorp, Netherlands
Purpose: Disease progression in osteoarthritis (OA) is often focusing
on cartilage loss on radiographs, but this has several limitations.
Biomarkers could be an alternative outcome measure, especially multiple
measurements over time. We measured uCTX-II, sCOMP, uCTX-I and
hsCRP over 6 years in OA and investigated their association with
radiographic progression.
Methods: 125 patients (mean age 59.6 years, 79% female) from the
GARP (Genetics ARthrosis Progression) cohort, all with symptomatic OA
at multiple sites (multiple sites in the hands or OA in two or more
of the following joint sites: hand, spine, knee, or hip), who attended
all follow-up visits, were studied. At 6-month, 1-year, 2-years, and
6-years uCTX-II (marker of cartilage degradation) and uCTX-I (marker
of bone turnover) were measured by ELISA, sCOMP (marker of cartilage
turnover) by immunoassay and hsCRP (marker of inﬂammation) by
immunonephelometry; data over time were summarized as area under
the curve (AUC). Radiographs were scored in two pairs: baseline and
2-years, baseline and 6-years, using the OARSI atlas for joint space
narrowing (JSN) graded 0 to 3 in the tibiofemoral, hip, DIP, PIP, IP-1,
CMC-1, MCP and STT joints, summing up to a total score (ranging from
0 to 105). With logistic regression analysis in generalized estimated
equations we calculated odds ratios of OA progression (deﬁned as JSN
score changes above smallest detectable change) at 2- and 6-years for
patients in the second and third AUC tertile relative to the ﬁrst AUC
tertile of biomarkers. Odds ratios were transformed in risk ratios (RRs
with (95% CI). Adjustments were made for age and sex.
Results: During 2- and 6-years follow-up, 36% and 54% patients,
respectively, showed OA progression. All baseline levels showed a
positive, but non-signiﬁcant, association with OA progression over 2
and 6 years, except for hsCRP over 6 years. Progressors over 2 years
showed consistent higher AUCs as compared to non-progressors, except
for sCOMP. This was most clear for the AUC of uCTX-II (mean difference
of 864.1 (95% CI 32.6 to 1760.8), p-value-0.05). Patients in the highest
AUC tertile of uCTX-II at 6, 12 and 24 months had a RRs of 2.9 (1.6 to
4.1), 1.8 (1.1 to 2.5) and 1.9 (1.1 to 2.7) to have OA progression at 2-years,
respectively. Patients in the highest AUC tertile of uCTX-II at 6, 12 and
24 months had a RRs of 1.6 (1.1 to 2.0), 1.5 (0.9 to 1.9) and 1.8 (1.2 to 2.2)
to have OA progression at 6-years, respectively. Other biomarkers AUC
tertiles were not associated with OA progression.
Conclusions: While baseline levels of biomarkers are not informative for
OA progression, multiple measurements of uCTX-II (summarized as AUCs
at various time points) are shown to be associated with 2- and 6-years
OA progression. Further studies to investigate uCTX-II as biomarker for
prognosis or evaluation of efﬁcacy of intervention are warranted.
